Duke Clinical Research Institute

The winter months can be a time to rest and unwind – but they can also bring with them increased health challenges, such as higher risks of heart attacks. DCRI’s Nishant Shah discusses what’s behind these risks, and measures to help reduce them: https://lnkd.in/eTUdSm5X #clinicalresearch #hearthealth #heartattack #cardiology

The ERASE-KD consortium, led by the DCRI and The Samuel DuBois Cook Center on Social Equity at Duke University, aims to implement interventions that address disparities in kidney health linked to structural racism. DCRI Faculty member and co-principal investigator Christina Wyatt says she and other consortium members will “work together to create, implement, and assess meaningful strategies aimed at breaking down or lessening the effects of structural racism.” https://lnkd.in/ejY2K4Pg #clinicalresearch #kidneydisease #healthequity #structuralracism

DCRI’s Sreekanth Vemulapalli joins other experts in exploring why mortality rates after transcatheter aortic valve replacement (TAVR) plateaued since 2019, despite modest declines in patient-level risk and procedural improvements over the same time period. Read more: https://lnkd.in/eFb7X7Ns #clinicaltrials #clinicalresearch #cardiology

New research featuring the DCRI’s Stephen Greene duke looks at how prescriptions for angiotensin receptor-neprilysin inhibitors among patients with #HFrEF have changed following the FDA’s approval of sacubitril-valsartan in 2015. Read more to learn how the prescribing trends have changed, and what future work remains to be done: https://lnkd.in/e2TV-uhe #clinicaltrials #clinicalresearch #prescriptions

Despite strong clinical guideline suggestions, the implementation of guideline‐directed medical therapy for patients with heart failure after a hospitalization remains low. According to the CONNECT-HF trial, use of this therapy style at discharge led to continued usage over time, highlighting the importance of starting treatment while a patient is hospitalized. Read more about these insights from the trial, which was designed and led by the DCRI and features contributions from the DCRI’s Satoshi Shoji, Lisa Kaltenbach, Michael Felker, Chris Granger, Adrian Hernandez, and Adam DeVore: https://lnkd.in/egg7Mvgc #clinicaltrials #clinicalresearch #heartfailure #GDMT

A new paper from the Heart Failure Society of America covers why it’s worth the effort to provide palliative care to patients with heart failure, as well as clarity for clinicians and institutions on what that care involves and how to deliver it. DCRI Faculty member and HFSA President Michael Felker says that despite the shortages in specialists in both HF and palliative care, “palliative care is something every clinician can help with [and] participate in.” https://lnkd.in/eSKTVCB7 #cardiology #heartfailure #patientcare #palliativecare

Many medications that are prescribed to children are often not studied in pediatric populations, leaving questions about the safety, effectiveness, and dosing for the youngest of patients. The Pediatric Trials Network has been working since 2010 to help change that. Learn more about the important work being done by the network in this recent article by DCRI’s Daniel K. (Danny) Benjamin, Jr., Principal Investigator and Network Chair, and Rachel Greenberg, Chair of the Network Steering Committee: https://lnkd.in/eVu2Hi2b #clinicaltrials #clinicalresearch #pediatrics

Earlier this week, Cytokinetics announced the start of COMET-HF, a Phase 3 trial conducted in collaboration with the DCRI that aims to test omecamtiv mecarbil in patients with symptomatic heart failure (HF) with severely reduced ejection fraction. Learn more about what this exciting collaboration could mean for future heart failure treatments: https://lnkd.in/eYRHM_m8 #clinicaltrials #clinicalresearch #heartfailure

At #AHA24, DCRI faculty and fellows participated in more than 40 sessions, where they shared new research results, insights, guidelines, and more. Get caught up on some of the top highlights and headlines from this year’s conference here: https://lnkd.in/dR6S4SWq #clinicaltrials #clinicalresearch #cardiology

In a recent project with the FDA, DCRI’s Shelby Reed & her fellow members of the DCRI PrefER Group designed a discrete-choice experiment to quantify tradeoffs that patients would accept between a decreased risk of clinically driven target-vessel revascularization and increased mortality risk, which may serve as a model for future collaborative efforts including patients, clinicians, researchers, regulatory partners, and industry to further define patient preferences and goals of care. Read more: https://lnkd.in/e-_H9Q9i #clinicaltrials #clinicalresearch #patientchoice #cardiology